M ore than 100,000 patients are waiting for a kidney transplant in the United States. In 2012, only 15,967 patients received a kidney and 5209 died waiting for one. 1 Among those
waiting, approximately 14% were sensitized to HLA antigens due to exposures from prior transplants, transfusions, or pregnancies. 1 Alloimmunization to HLA is well recognized as a potentially serious and relatively common complication of transfusions. 2 HLA antigens are present on both platelets (PLTs) and white blood cells (WBCs). Red blood cells (RBCs) do not generally express HLA antigens, but BennettGoodspeed antigens may occasionally be present and lead to HLA alloimmunization. More importantly, RBC units contain a large number of WBCs, which historically led to high rates of HLA alloimmunization. 3 While leukoreduced
RBCs are often transfused, these units still may contain up to five million WBCs and stimulate HLA antibody formation. 4 PLT transfusion may lead to HLA antibodies directed against Class I HLA epitopes and exposure to WBCs from RBC transfusion may lead to HLA antibodies directed against Class I and II HLA epitopes. 5, 6 HLA sensitization resulting from transfusion is less robust and generally shorter lived than that resulting from transplantation. However, immunoglobulin (Ig)G HLA antibodies to a transplanted organ negatively impact graft function and graft survival, regardless of the route of sensitization. Unfortunately, many renal transplant patients require transfusion support, either during the perioperative period due to decreasing hemoglobin associated with therapeutic plasma exchange (TPE) desensitization to undergo an HLAincompatible (HLAi) renal transplant or while the patient is on hemodialysis. The role of transfusion in HLA antibody development has long been widely recognized by the transfusion, transplant, and nephrology communities; 7, 8 however, data are limited on whether blood transfusions are associated with increased risk of antibody-mediated rejection (AMR). 9 Furthermore, transfusion has been shown to increase both the breadth and the strength of HLA antibodies in sensitized patients. 10 This retrospective cohort study evaluated the impact of leukoreduced RBC and PLT transfusions on AMR in sensitized patients undergoing HLAi renal transplantation. All participants in this study had HLA antibodies. HLA incompatibility was defined by three measures of antibody strength: complement-dependent cytotoxic (CDC) crossmatch, flow-cytometric crossmatch, or detectable donorspecific HLA antibodies on multiplex bead assay performed on the Luminex platform. Participants were excluded if the transplant donor was also ABO-incompatible or if the patient currently or previously had documented non-HLA endothelial antibodies.
MATERIALS AND METHODS

Study population
Immunosuppression and desensitization
Alternate-day, single-volume TPE and 100 mg/kg intravenous immunoglobulin (IVIG; cytogam, MedImmune) were utilized to decrease HLA titers to preoperative donor-specific antibodies (DSAs) below a cytotoxic crossmatch level, as previously described. 11, 12 Mycophenolate mofetil (2 g/day) and tacrolimus (to a serum level of 8-10 ng/mL) were initiated at the same time as TPE treatments. 13, 14 Preoperative rituximab was used selectively for those who had a high-risk donorrecipient phenotype, such as those starting with a high-titer crossmatch, with multiple repeated mismatches, and with high levels of donor HLA-specific B cells. 15 Intraoperatively, induction therapy included interleukin (IL)-2 receptor antibody (anti-CD25, daclizumab 2 mg/kg) or thymoglobulin (1.5 mg/kg per day × 5 days). 13, 14 Triple-drug immunosuppression was composed of tacrolimus, mycophenolate mofetil, and steroids. When the tacrolimus level reached 8 to 12 ng/mL, the prednisone dose was decreased to 20 mg/day and, after the first month, tapered to 5 mg/day by 3 months posttransplant. TPE was continued postoperatively until the DSA strength was below a flow cytometric crossmatch level. After TPE was discontinued, it was restarted if indicated by clinical data including biopsy results, increasing DSAs, increasing serum creatinine, and/or a diagnosis of AMR.
Transfusions
Leukoreduced RBC transfusions were given strictly based on clinical need, following standard transfusion practices. 16 However, patients were maintained with a hematocrit level of more than 22% while receiving TPE. Apheresis PLT transfusions were also given based on clinical need, following standard transfusion practices. 17 Patients with chronic stable thrombocytopenia were transfused at a threshold based on their degree of bleeding, in general transfusing to keep the level greater than 10 × 10 9 /L in a nonbleeding patient. Before transplant, patients were transfused to a PLT count of 50 × 10 9 /L. 17, 18 The vast majority of study subjects who received transfusions (93%, 169/182) were under immunosuppression during all times of their transfusions.
Histopathologic analysis of biopsies and diagnosis of rejection
Biopsies were obtained when clinically indicated or by protocol. Surveillance biopsies were performed at 1, 3, 6, and 12 months after transplant. All biopsies were analyzed by routine light microscopy using hematoxylin-eosin, periodic acid-Schiff, methenamine silver, and Masson's trichrome stains. For all biopsies, a small (3-to 4-mm) piece of cortical or medullary tissue was also taken for C4d staining, which was performed by indirect immunofluorescence or cryostat sections using a mouse monoclonal anti-human C4d antibody (Quidel) at 1:40 dilution, followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Jackson Immunoresearch Laboratories). 19 Staining for C4d in peritubular capillaries (PTCs) was graded as diffuse (positive in > 50% of specimen), focal (10%-50%), or absent (<10%). Clinical and subclinical acute cellular rejections were graded according to the 2013 International Banff classification. 20 AMR (clinical or subclinical) was diagnosed as being present when the following criteria were met-1) positive (diffuse or focal) C4d staining in PTC; 2) at least one of the following: marginated WBCs (neutrophils or mononuclear cells) in at least 10% of cortical PTCs, moderate or severe glomerulitis (Banff g score > 2), or transmural necrotizing arteritis; and 3) DSAs being detectable in the serum.
Antibody testing
HLA antibody levels were determined before and after the first, pretransplant TPE procedure. Thereafter, HLA antibody levels were determined after each TPE. HLA Class I and II DSAs were identified by using a color-coded multianalyte bead immunoassay on the Luminex platform, which uses beads coated with soluble HLA molecules as targets (LABScreen single antigen Class IVCombi and LABScreen single antigen Class II antibody detection TestVGroup 1; One Lambda, Thermo Fisher Scientific) supplemented with phenotype panels (LIFECODES Class I ID, LIFECODES Class II IDv2, Immucor). The multianalyte immunoassays were performed according to the manufacturer's instructions as reported elsewhere.
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Statistical analysis
The 244 consecutive patients who received an HLAi kidney transplant were categorized into three groups based on transfusion within 4 weeks before or after the transplant: no transfusion (n = 62), RBCs only (n = 162), and RBCs and PLTs (n = 20). The Cox model was used to assess the association between transfusion and AMR. Items considered as potential confounders included age at transplant, sex, race, primary cause of end-stage renal disease (ESRD), panelreactive antibody (PRA), previous transplant, time on dialysis, HLA antibody strength, and TPE before transplant. For the adjusted model, potential confounders that showed significance (p < 0.20) in univariate analyses were included. The primary analysis did not include the impact of TPE events after transplant or after transfusion since posttransplant TPE may be initiated for possible concern for AMR before a biopsy being performed and we did not want to bias the results. However, an additional multivariate analysis was performed that included posttransplant TPE in addition to the potential confounders included in the primary model.
Two sensitivity analyses were performed. A sensitivity analysis was performed to evaluate only individuals who were transfused during the day of surgery and within 4 weeks of transplant. A second sensitivity analysis was performed among those who received PLTs. These individuals were categorized by the types of PLTs they received and compared with those who received no transfusion. HLAselected PLTs were those in which all donor antigens were avoided, HLA-unselected PLTs were those for which donor antigens were not avoided, and HLA-unknown PLTs were those for which the PLT antigens were unknown. The Cox model was used to assess the association between level of match and AMR. The adjusted model included the following potential confounders: transfusion, PRA, time on dialysis, HLA antibody strength, and number of TPE treatments before transplant.
RESULTS
Patients and matched control subjects
For the 244 HLAi kidney transplant patients, the demographic and clinical data are summarized in Among patients who received no transfusions, only-RBC transfusions, or RBC and PLT transfusions, there were no significant differences in age at transplant, male-tofemale ratio, or racial ethnicity. The most common cause of ESRD was glomerular disease, with other common causes including diabetes mellitus, hypertensive nephrosclerosis, polycystic kidney disease, and vascular disease. There was no significant difference in the PRA, with a median (IQR) of 86% (52%-96%) for those who did not receive transfusion, 93% (70%-100%) for those who received RBCs only, and 93% (66%-97%) for those who received both RBCs and PLTs. A previous kidney transplant had occurred in 48% of patients who did not receive transfusion, in 54% of those who received RBCs, and in 65% of those who received RBCs and PLTs. Mean time on dialysis was also similar among the groups, with most patients on dialysis for between 2 and 6 years and very few not on dialysis before transplant. HLA antibody strength was significantly different among the three groups, with the highest level (pretransplant CDC positive) occurring most often in those who received both RBC and PLT transfusions (p = 0.026). The number of TPE treatments was also significantly higher among those transfused (p < 0.001).
AMR
The number of patients with clinical or subclinical AMR was similar between the three groups, with 34% of those who did not receive transfusion developing AMR, 43% of those who received RBCs only developing AMR, and 35% of those who received RBCs and PLTs developing AMR. Patient characteristics associated with AMR are shown in Table 2 . In the unadjusted model, a PRA of more than 80, at least 6 years on dialysis, higher HLA antibody strength, and greater number of TPE treatments showed significant risk associated with AMR. After adjustment, however, only HLA antibody strength remained significant (adjusted hazard ratio [adjHR] 2.23, 95% CI 1.10-4.52; CDC positive compared to Luminex positive). Differences in age at transplant, sex, race, cause of ESRD, and history of previous transplant were not associated with a significant risk for AMR. Compared to those who received no transfusions, patients who received RBCs only were no more likely to develop AMR (adjHR 1.00, 95% CI 0.59-1.69). For each 1-unit increase in RBC transfusions, there was no association with increased risk of AMR (adjHR 0.94, 95% CI 0.85-1.05, p = 0.3). Receiving both RBCs and PLTs was not associated with developing AMR (adjHR 0.68, 95% CI 0.28-1.68). A 1-unit increase in PLT transfusion was not associated with any change in AMR risk (adjHR 0.97, 95% CI 0.90-1.05, p = 0.5).
In an additional multivariate analysis also including posttransplant TPE, posttransplant TPE procedures were highly associated with AMR (three to five procedures adjHR 1.73, 95% CI 0.92-3.24; five or more procedures adjHR 5.25, 95% CI 2.85-9.66; compared to two or fewer procedures). In this model, however, transfusions were still not associated with AMR (RBC-only transfusion adjHR 0.80, 95% CI 0.47-1.37; RBC and PLT transfusion adjHR 0.70, 95% CI 0.28-1.74).
In a sensitivity analysis that focused on only those under immunosuppression at the time of transfusion and excluded the 13 individuals transfused before the day of transplantation, transfusions were not associated with increased risk of AMR (compared to those not transfused, RBC transfusion on the date of transplant aHR 1.33, 0.84-2.12; RBC transfusion posttransplant aHR 0.85, 0.50-1.43).
Another sensitivity analysis was performed for patients who received both RBCs and PLTs, which is summarized in Table 3 . There were a total of 11 patients who received PLTs, which avoided donor HLA antigens; three of these developed AMR and eight of them did not (adjHR 0.43, 95% CI 0.12-1.50, compared to no-transfusion group). Three patients received PLTs that were known to have donor antigens; one of these developed AMR and two did not (adjHR 1.38, 95% CI 0.18-10.46, compared to no-transfusion group). For six patients, the PLT HLA type was not known; three of these developed AMR and three did not (adjHR 0.95, 95% CI 0.27-3.33, compared to no-transfusion group).
DISCUSSION
Patients undergoing HLAi renal transplants have a survival benefit compared to those who wait for deceased donors. 23 However, patients undergoing HLAi renal transplantation often require blood transfusions. Many surgeons hesitate to transfuse their patients in the perioperative period due to a presumed increased risk of AMR with transfusion from HLA antigen exposure from blood products. This retrospective cohort study of 244 renal transplant patients who had donor-specific anti-HLA antibodies who underwent desensitization with a standardized protocol including TPE and IVIG found no association between transfusion and increased risk of AMR. A multivariate analysis controlling for PRA, number of years on dialysis, HLA antibody strength, and number of TPE treatments and transfusions showed that only HLA antibody strength before transplantation was associated with the development of AMR.
Although it is well established that prior transfusions, pregnancy, and transplants can lead to HLA sensitization, 24 the role of perioperative transfusion in HLAi transplants and its effect on long-term outcome after transplant has been unclear. Because these transfusions are given under the cover of immunosuppression, a B-cell response may be blunted or prevented. Known factors that contribute to transplant outcomes include those based on the donor (i.e., quality of the transplanted kidney), those based on the recipient (i.e., age, ethnicity, time spent on dialysis, and cardiovascular complications at the time of transplant), and finally those based on the compatibility of the donor and the recipient (i.e., HLA compatibility and anti-HLA immunization). 25 Other factors that have bearing on graft function and survival include recurrence of native disease, delayed graft function in the immediate posttransplant period, glomerular filtration rate, proteinuria, chronic allograft dysfunction, and types of immunosuppression.
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Of note, some of the patients in our study received PLTs selected to avoid donor antigens with the intention of reducing the risk of inciting an immune response and increasing a patient's DSA and, therefore, the risk of AMR. The patients who received HLA-selected PLTs had a lower incidence of AMR than those who did not receive HLAselected PLTs; however, because the numbers were small the results did not reach significance. Based on these study results, apheresis PLTs and leukoreduced RBCs administered in the peritransplant period do not appear to be associated with AMR in HLAi renal transplant recipients; however, PLTs should be given cautiously and an attempt should still be made to give HLA-selected PLT products.
This study has several limitations. This is a retrospective, single-center study in a large referral center; therefore, these findings should be replicated in a prospective, multicenter study with a more heterogeneous population. We evaluated only HLAi live donor transplants, and it would be of interest to study all kidney transplant recipients, including deceased donor transplants with DSA. The majority of renal transplant AMR is caused by HLA antibodies, but other antibodies, such as anti-endothelial cell antibodies or angiotensin II receptor Type 1 antibodies, may also lead to AMR. While this study focused on HLA, the findings of this study suggest that blood transfusions are not associated with an increased risk of AMR from any type of antibody. Since we did not find an increased risk of AMR associated with transfusion, we did not evaluate the possible etiology.
The final multivariable model also did not incorporate posttransplant factors, such as medication noncompliance or infection. Although we have a large referral service, the final number of patients who received PLTs in our study is small, and approximately half of these patients received PLTs known to contain no donor HLA antigens. When these patients were considered separately, differences in AMR rates did not reach significance. Patients who have higher antibody titers tended to receive more TPE treatments. Furthermore, those receiving TPE during desensitization for an HLAi kidney transplant commonly require blood products. The more TPE sessions they receive, the more likely they will need to be transfused. In the perioperative transplant period when these transfusions occur the patients were receiving induction therapy and high doses of maintenance immunosuppression. The patients were receiving both humoral (IVIG, rituximab, mycophenolate mofetil) and cellular-mediated (IL-2 receptor antibody, tacrolimus, mycophenolate mofetil) immunosuppression. Thus, the immunosuppression might offer protection from the additional HLA exposure triggering an AMR episode.
In patients who are already highly sensitized against HLA-that is, those who have already proven they can make anti-HLA antibodies-leukoreduced RBC and PLT transfusions in the perioperative period do not place them at any higher risk for AMR. We recognize that selecting PLTs that avoid donor antigens may be particularly difficult, if not impossible, in these already highly sensitized patients. However, this study also suggests that when HLA selection can be accomplished with the resources available, it is reasonable to attempt to provide these products for highly sensitized patients. Further prospective, controlled multicenter studies, including studies of patients who receive HLAcompatible organs, will be necessary to determine if RBC or PLT transfusions in the peritransplant period increase sensitization or negatively impact outcomes.
